Health

STAT+: Roche gets a lung cancer win with its KRAS drug divarasib

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 27/10/2026, 06:36:25 UTC.

Briefings

A Roche study of divarasib, a KRAS inhibitor, achieved a second-line lung cancer win against older Amgen and Bristol Myers Squibb drugs at the 2026 ESMO conference. The evidence indicates superior performance in second-line advanced non-small cell lung cancer, though the specific patient numbers and exact efficacy percentages are not detailed in the provided text.

Key points

• Roche's divarasib demonstrated superior performance in second-line advanced non-small cell lung cancer compared to older inhibitors from Amgen and Bristol Myers Squibb.
• The study was conducted at the 2026 ESMO conference, with the specific patient count and efficacy percentage not provided in the source.

Context

This finding comes from the 2026 ESMO conference, a major European cancer conference where Roche presented data on its KRAS inhibitor divarasib. The study focused on second-line treatment for advanced non-small cell lung cancer, challenging the status quo of older inhibitors from Amgen and Bristol Myers Squibb.

Limitations

The provided evidence is limited to a summary of the 2026 ESMO conference presentation. Specific patient numbers, exact efficacy percentages, and detailed statistical outcomes are not included in the source text.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 27/10/2026, 07:36:38 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeigubi2q3kn7zpepqqottytmqkbw4mmkzikzywca5cfcibfn5n7whm